Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study

Abstract

Previous studies have suggested that the sulphonylurea hypoglycaemic agent gliclazide has specific effects in inhibiting platelet aggregation, and other haemorrheological effects that could be beneficial in preventing diabetic microangiopathy. A double-blind trial of the effect of gliclazide on platelet aggregatory responses was performed in 51 diabetic patients. Insulin- and non-insulin-treated diabetics were assessed during an initial 12-month placebo period, and in a subsequent 24-month active period after randomisation into placebo and gliclazide groups in insulin-treated patients or to glibenclamide and gliclazide groups in non-insulin-treated patients. Platelet-rich plasma was obtained..